At a glance
This program funds early-stage research on Duchenne muscular dystrophy that could lead to new treatments, new delivery methods, better models, or biomarkers, with a focus on safe and effective therapies and primary disease pathology. Eligible applicants include U.S. Department of War organizations and foreign or domestic, for-profit or nonprofit, public or private organizations; the principal investigator must be an independent investigator, with separate categories for established investigators, early-stage new investigators, and investigators transitioning from another field. The program expects to fund about 5 awards totaling roughly $2.5 million, with a total cost cap of $500,000 per award and a maximum project period of 2 years. Cost sharing is not required, and clinical trials are not allowed. The announcement does not state a geographic restriction, but it does note that painful research involving domestic cats or dogs is not supported except for military or service animal studies.
What it funds
Official description from grants.gov
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals. Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories: • The Established Investigator category is for independent investigators at all academic levels, or equivalent • The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators. • The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators. Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required for all applications. Clinical trials or clinical trial aims are not allowed.
Who can apply
- Unrestricted